Main content

    Epilepsy Clinical Trials

    California Pacific Epilepsy Program Opens new window | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Active Trials

    Title: A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1
    Description: The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters. There are two arms to this study: 5 mg intranasal midazolam (USL261) vs intranasal placebo.
    Investigator: Kenneth Laxer, MD
    Eligibility: Subjects 18 years of age or older with a documented history of seizure clusters lasting a minimum of 10 minutes
    Status: Coming soon
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study Upsher-Smith P261-401

    Title: NeuroPace RNS® System Post-Approval Study in Epilepsy
    Description: This study is to follow patients prospectively over 5 years in the real-world environment to gather data on the long-term safety and effectiveness of the RNS System at qualified Comprehensive Epilepsy Centers by qualified neurologists, epileptologists, and neurosurgeons trained on the RNS System
    Investigator: David King-Stephens, MD
    Eligibility: Subjects 18 years of age or older with frequent, disabling seizures (SPS motor, CPS, or secondarily generalized seizures) and who have failed treatment with a minimum of 2 AEDs, undergone diagnostic testing that has identified no more than 2 epileptogenic foci and who are able to maintain a seizure diary alone or with the assistance of a competent individual
    Status: Open to enrollment
    Contact: Douglas Raggett, RN, 415-600-3777, Email: RaggettD@cpmcri.org about Study NeuroPace PAS

    • updated January 2016